Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Journal of Oncology Practice
|
October 25, 2019
Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors
Kathryn F Mileham, Caroline Schenkel, Meredith K Chuk, et al.
Therapeutic Innovation & Regulatory Science
|
September 1, 2020
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer
Phil Bonomi, Nina Stuccio, C J Delgra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 15, 2013
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma
Elizabeth Fox, Brigitte C Widemann, Meredith K Chuk, et al.
Pediatric Blood & Cancer
|
April 26, 2018
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group
Meredith K Chuk, Brigitte C Widemann, Charles G Minard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
Elizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2017
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma
Meredith K Chuk, Jennie T Chang, Marc R Theoret, et al.
The Lancet. Oncology
|
January 24, 2018
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
Julia A Beaver, Maitreyee Hazarika, Flora Mulkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2017
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
Maitreyee Hazarika, Meredith K Chuk, Marc R Theoret, et al.
Cancer
|
May 12, 2017
Clinical trial enrollment of adolescents and young adults with sarcoma
Lara E Davis, Katherine A Janeway, Aaron R Weiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC
Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Journal of Oncology Practice
|
October 25, 2019
Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors
Kathryn F Mileham, Caroline Schenkel, Meredith K Chuk, et al.
Therapeutic Innovation & Regulatory Science
|
September 1, 2020
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer
Phil Bonomi, Nina Stuccio, C J Delgra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 15, 2013
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma
Elizabeth Fox, Brigitte C Widemann, Meredith K Chuk, et al.
Pediatric Blood & Cancer
|
April 26, 2018
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group
Meredith K Chuk, Brigitte C Widemann, Charles G Minard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
Elizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2017
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma
Meredith K Chuk, Jennie T Chang, Marc R Theoret, et al.
The Lancet. Oncology
|
January 24, 2018
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
Julia A Beaver, Maitreyee Hazarika, Flora Mulkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2017
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
Maitreyee Hazarika, Meredith K Chuk, Marc R Theoret, et al.
Cancer
|
May 12, 2017
Clinical trial enrollment of adolescents and young adults with sarcoma
Lara E Davis, Katherine A Janeway, Aaron R Weiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC
Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, et al.
Page
of 2